D McLeod
Academic Department of Ophthalmology, Manchester Royal Eye Hospital, Manchester, UK E-mail: david.mcleod@nhs.net We are grateful to Dr McLeod 1 for the interest that he has shown in our paper. 2 Rather, then there being a conspiracy to increase the confusion within central retinal artery occlusion (CRAO), our study demonstrates that the disease is incompletely understood. In particular, we disagree with Dr McLeod that the retinal penumbra lasts for more than 24 h. Retinal and cerebrovascular ischaemia share a number of common pathophysiological features and is reflected by the recent extended definition of stroke involving retinal as well as cerebral ischaemia. 3 In vitro experiments show that when neuronal cells are deprived of oxygen, that within 5 s, there is evidence of neuronal dysfunction. Within 10 s, cell death occurs. The elegant experiment of Astrup et al 4 demonstrated that the penumbra is a function of collateral perfusion and that if there was no resolution of the occlusion, then eventually the penumbra would fail, and infarction would be permanent.
In cerebral stroke using perfusion imaging, various groups have demonstrated that the ischaemic penumbra may persist beyond 24 h. However, randomised controlled trials of reperfusion therapy in acute stroke have demonstrated on that in the majority of individuals, the ischaemic penumbra only extends out to 4.5 h and at maximum, 6 h. 5, 6 The misperceptions that the retinal penumbra persists for 24 h, initially backed up by observational data, led to the design of two randomised controlled trials that recruited individual with central retinal artery occlusion of beyond 6 h. The EAGLE study recruited subjects up to 19 h of symptom onset, 7 while our group conducted a randomised controlled trial of intravenous tPA given to individuals within 24 h of symptom onset. 8 Both of these randomised controlled trials were negative studies, however, a signal was seen in individuals who receive tPA within 6 h of symptom onset. 8 We recently presented 2 the results of a 5-year retrospective consecutive series of HS cases at our regional neuroscience centre. Seventy-five (74 unilateral and 1 bilateral) cases, with a mean age of 49.7 years (SD ± 17 years, range 18-87 years), were identified from the electronic radiology card system and a case note review was carried out. Two cases were recurrent, and both episodes were recorded as one case. Forty-seven cases were clinically isolated, of these the commonest aetiology was undetermined cases (n ¼ 22) followed by carotid dissection (n ¼ 11).
Positive aetiology was found in four isolated HS cases who had no history of trauma or surgery, no reported headache, neck ache, or pain: two carotid dissections, one pancoast tumour, and one C1 benign aneurysmal boney cyst. Our main concern is, if a HS is only reviewed at 6 weeks as suggested by the algorithm, instead of undergoing prompt imaging, patients with carotid dissection are at significant risk of a ischaemic event (transient ischaemic attack or stroke) within the first 31 days of onset of symptoms. 3 Positive aetiology was found in three isolated HS cases who presented with history of greater than 1 year: two had carotid dissection and one a cervical sympathetic paraganglioma. Although we accept that no treatment would be warranted for the dissections at over 12 months, two recurrent cases of carotid dissection were found within our cohort. This highlights the importance of investigating the patient to fully inform them and clinician in the event HS recurs.
These findings suggest that an atraumatic nonpainful isolated HS or a chronic history of isolated HS should not be treated as benign entities. We would recommend prompt imaging in all cases. As suggested by Al-Moosa and Eggenberger, 4 a prospective study is required to provide evidence to determine what is the 'gold standard' imaging modality for isolated HS.
